Superluminal Medicines key facts
as of Oct 2026- Developer of a generative biology medicine technology intended to accelerate new possibilities in drug discovery and development.
- Superluminal Medicines is valued at approximately $576.3M as of Oct 2026, set at its Series B, Sep 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $157.7M across 4 recorded rounds; the latest was Series B ($65.5M) in Sep 2026.
- Notable investors include Insight Partners (New York), Gaingels, RA Capital Management, Evolution VC Partners, Nvidia — 12 tracked in total.
- Superluminal Medicines has filed 3 Form Ds with the SEC since 2023, most recently Aug 2025 ($5.0M sold to 1 investors).
- Status: Privately Held (backing).
Valued at $576.3M at its Series B, Sep 2026. Nothing has traded since.
- ·The post-money valuation on its round
- ·The complete investor list: 12 names
- ·Watch Superluminal Medicines: the Monday email on marks, rounds and moves
Superluminal Medicines funding rounds
4 roundsWho backs Superluminal Medicines
12+Superluminal Medicines valuation
Superluminal Medicines was valued at $576 million at its Series B in Sep 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
Recent activity
In the last 90 days, Superluminal Medicines's record added 1 funding round.
How much has Superluminal Medicines raised?
Superluminal Medicines has raised $158 million across 4 recorded rounds since 2023. The largest was a $65.5 million Series B in Sep 2026. 1 of the rounds disclosed a post-money valuation.
Superluminal Medicines has filed 3 Form Ds with the SEC since 2023, most recently in Aug 2025 ($5 million sold to 1 investor).
Superluminal Medicines investors
12 investors are on record for Superluminal Medicines, including Insight Partners (New York), Gaingels, RA Capital Management and Evolution VC Partners. By type, the record holds 5 venture capital firms, 1 hedge fund and 1 asset manager. The Series B in Sep 2026 drew 10 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: VeraDermics (NYS: MANE) ($596 million), Strand Therapeutics ($571 million) and Bambusa Therapeutics ($555 million).
About Superluminal Medicines
Developer of a generative biology medicine technology intended to accelerate new possibilities in drug discovery and development. The company creates candidate-ready compounds using a comprehensive combination of deep biology and chemistry expertise, machine learning and proprietary big data infrastructure, enabling the pharmaceutical industry to accelerate drug discovery and increase the probability of success in small molecule drug development.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2022
- Employees
- 29
- Website
- superluminalrx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.